Olanzapine induced weight gain
Conditions
Interventions
Test group: Antipsychotic drugs and life guidance,
(1)Single antipsychotic treatment of Olanzapine: Zaipule Tablets (marketed drug), 5mg/tablet, 28 tablets/box, produced by Lilly (China) Suzhou Pharma
Control:Antipsychotic drugs and life guidance,
(1)Single antipsychotic treatment of Olanzapine: Zaipule Tablets (marketed drug), 5mg/tablet, 28 tablets/box, produced by Lilly (China) Suzhou Pharmaceut
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ? Age 18-65 years old; ? BMI 18.5-23.9 kg/m2; ? Schizophrenic inpatients or outpatient patients diagnosed according to ICD-10. ? In recent three months, systolic blood pressure is 90-139mmHg, diastolic blood pressure is 60-89mmHg, Glycated hemoglobin is 4-6%, total cholesterol is 2.8-5.17mmol/L, triglyceride is 0.56-1.7mmol/L.
Exclusion criteria
Exclusion criteria: Potential participants who meet the inclusion criteria will be excluded if they meet any of the following criteria: ? Any other chronic disease that may affect the stability of Gut microbiota, such as immune deficiency, autoimmune disease, cancer, inflammatory intestinal disease, and diarrhea in the past three months; ? Use drugs that affect Gut microbiota in the past month, including antibiotics, glucocorticoids, cytokines, probiotics and biological agents; ? Those who have undergone gastroscopy, colonoscopy, or gastrointestinal barium meal in the past six months; ? Those who have undergone major gastrointestinal surgery (cholecystectomy and Appendectomy) and intestinal resection within 5 years; ? Individuals with limited mobility due to major physical or mental illnesses; ? In the past six months, there have been significant changes in eating habits (such as changing from meat and vegetarian diet to Vegetarianism); ? There is alcohol or other Substance abuse and dependence; ? Pregnant women; ? Abnormal liver and kidney function; ? Patients known to be allergic to any component of olanzapine and at risk of narrow angle glaucoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in body mass index;The incidence of weight gain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in blood sugar and blood lipids before and after;Changes in gut microbiota before and after; | — |
Countries
China
Contacts
Public ContactLi Wei-wei
Peking University First Hospital
Outcome results
None listed